Compare PHAR & VMET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHAR | VMET |
|---|---|---|
| Founded | 1988 | 2011 |
| Country | Netherlands | Canada |
| Employees | N/A | 8 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 956.7M |
| IPO Year | 2020 | N/A |
| Metric | PHAR | VMET |
|---|---|---|
| Price | $12.94 | $8.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $38.33 | N/A |
| AVG Volume (30 Days) | 4.5K | ★ 207.2K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.04 | $185.47 |
| Revenue Next Year | $2.51 | $16.05 |
| P/E Ratio | $3,041.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.55 | $8.57 |
| 52 Week High | $21.34 | $13.81 |
| Indicator | PHAR | VMET |
|---|---|---|
| Relative Strength Index (RSI) | 38.08 | 35.11 |
| Support Level | $11.88 | $8.57 |
| Resistance Level | $13.61 | $13.56 |
| Average True Range (ATR) | 0.46 | 0.43 |
| MACD | -0.11 | -0.00 |
| Stochastic Oscillator | 3.92 | 7.03 |
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
Versamet Royalties Corp is a diversified metals royalty and streaming company with exposure to a range of resource royalties and streams including gold, silver, copper, zinc, graphite and uranium, across a variety of jurisdictions. The Company's operating segments are considered to be its individual royalties, streams and the Greenstone gold interest.